Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12.

Yu, Tosol,Kang, Hyun-Cheol,Lim, Do Hoon,Kim, Il Han,Chung, Woong-Ki,Suh, Chang-Ok,Choi, Byung Ock,Cho, Kwan Ho,Cho, Jae Ho,Kim, Jin Hee,Park, Chul-Kee,Hong, Yong-Kil,Kim, In Ah M. Nijhoff ; Kluwer Academic Publishers 2015 Journal of neuro-oncology Vol.121 No.3

<P>This study investigated the treatment of anaplastic oligodendroglial tumors across nine Korean institutions. We reviewed the medical records from 381 patients with histologically confirmed anaplastic oligodendroglioma or anaplastic oligoastrocytoma (AOA) from 2000 to 2010. Clinical factors and treatment patterns were analyzed for each year. Post-operative therapy was performed in 354 patients (94.1 %), of which 133 received radiotherapy (RT) alone and 189 received both RT and chemotherapy. RT alone was the preferred treatment toward the end of the study period (29.4 % in 2000-2001 vs. 56.3 % in 2010, P = 0.005). The use of procarbazine, lomustine, and vincristine (PCV) decreased (57.6 % in 2000-2001 vs. 28.6 % in 2010, P = 0.001) and the use of temozolomide (TMZ) increased (0 % in 2000-2001 vs. 61.9 % in 2010, P < 0.001) over the study period. A combination of chemotherapy and RT was used more often than RT alone in young patients (P = 0.036) and patients with a good performance status (P = 0.023). The 1p/19q co-deletion status and O-6-methyguanine-DNA methyltransferase methylation were analyzed since 2004 but were not significant factors for determining whether to administer chemotherapy. Among the patients who received chemotherapy, TMZ was used more often in patients with AOA (P = 0.007) and PCV was used more often in patients with either multiple lesions (P = 0.027) or the 1p/19q co-deletion (P = 0.026). Our results demonstrate that the treatment pattern for oligodendroglial tumors changed significantly across the study period. In particular, TMZ has replaced PCV, and the use of molecular markers as well as RT alone has increased, but a unified protocol remains to be established.</P>

Outcome analysis in patients with uterine sarcoma

Tosol Yu,MD,Hak Jae Kim,MD,PhD,Hong-Gyun Wu,MD,PhD,Sung Whan Ha,MD,PhD,Yong-Sang Song,MD,PhD,Noh-Hyun Park,MD,PhD,Jae-Won Kim,MD,PhD 대한방사선종양학회 2015 Radiation Oncology Journal Vol.33 No.1

Purpose: To analyze the prognostic factors for survivals and to evaluate the impact of postoperative whole pelvic radiotherapy (WPRT) on pelvic failure in patients with uterine sarcoma treated with radical surgery. Materials and Methods: We retrospectively analyzed 75 patients with uterine sarcoma who underwent radical surgery with (n = 22) or without (n = 53) radiotherapy between 1990 and 2010. There were 23 and 52 patients with carcinosarcoma and non-carcinosarcoma (leiomyosarcoma, 22; endometrial stromal sarcoma, 25; others, 5), respectively. The median follow-up period was 64 months (range, 17 to 269 months). Results: The 5-year overall survival (OS) and pelvic failure-free survival (PFFS) of total patients was 64.2% and 83.4%, respectively. Multivariate analysis revealed that mitotic count (p = 0.006) was a significant predictor of OS. However, factors were not found to be associated with PFFS. On analyzing each of the histologic subtypes separately, postoperative WPRT significantly reduced pelvic failure in patients with carcinosarcoma (10.0% vs. 53.7%; p = 0.046), but not in patients with non-carcinosarcoma (12.5% vs. 9.9%; p = 0.866). Among the patients with carcinosarcoma, 4 patients (17%) had recurrence within the pelvis and 3 patients (13%) had recurrence in other sites as an initial failure, whereas among the patients with non-carcinosarcoma, 3 patients (6%) experienced pelvic failure and 13 patients (25%) experienced distant failure. Conclusion: The most significant predictor of OS was mitotic count. Based on the improved PFFS after postoperative WPRT only in patients with carcinosarcoma and the difference in patterns of failure between histologic subtypes, optimal adjuvant treatment options should be offered to patients based on the risk of recurrence patterns.

Outcome analysis in patients with uterine sarcoma

Yu, Tosol,Kim, Hak Jae,Wu, Hong-Gyun,Ha, Sung Whan,Song, Yong-Sang,Park, Noh-Hyun,Kim, Jae-Won The Korean Society for Radiation Oncology 2015 Radiation Oncology Journal Vol.33 No.1

Purpose: To analyze the prognostic factors for survivals and to evaluate the impact of postoperative whole pelvic radiotherapy (WPRT) on pelvic failure in patients with uterine sarcoma treated with radical surgery. Materials and Methods: We retrospectively analyzed 75 patients with uterine sarcoma who underwent radical surgery with (n = 22) or without (n = 53) radiotherapy between 1990 and 2010. There were 23 and 52 patients with carcinosarcoma and non-carcinosarcoma (leiomyosarcoma, 22; endometrial stromal sarcoma, 25; others, 5), respectively. The median follow-up period was 64 months (range, 17 to 269 months). Results: The 5-year overall survival (OS) and pelvic failure-free survival (PFFS) of total patients was 64.2% and 83.4%, respectively. Multivariate analysis revealed that mitotic count (p = 0.006) was a significant predictor of OS. However, factors were not found to be associated with PFFS. On analyzing each of the histologic subtypes separately, postoperative WPRT significantly reduced pelvic failure in patients with carcinosarcoma (10.0% vs. 53.7%; p = 0.046), but not in patients with non-carcinosarcoma (12.5% vs. 9.9%; p = 0.866). Among the patients with carcinosarcoma, 4 patients (17%) had recurrence within the pelvis and 3 patients (13%) had recurrence in other sites as an initial failure, whereas among the patients with non-carcinosarcoma, 3 patients (6%) experienced pelvic failure and 13 patients (25%) experienced distant failure. Conclusion: The most significant predictor of OS was mitotic count. Based on the improved PFFS after postoperative WPRT only in patients with carcinosarcoma and the difference in patterns of failure between histologic subtypes, optimal adjuvant treatment options should be offered to patients based on the risk of recurrence patterns.

Verification of Balloon Catheter for Rectal Dose Reduction in Brachytherapy

유도솔(Tosol Yu),문영민(Young Min Moon),전완(Wan Jeon),최철원(Chulwon Choi),배상일(Sang Il Bae),김진영(Jin-young Kim) 한국방사선학회 2022 한국방사선학회 논문지 Vol.16 No.6

기존 강내방사선치료 시스템은 직장 출혈 등의 부작용을 줄여주고자 직장견인기, 젖은 거즈 등을 이용하여 직장과 탄뎀과의 거리를 늘려주고자 하나 질 내 좁은 입구로 삽입이 어렵고 재현성이 떨어지는 단점이 존재하였다. 이에 본 논문에서는 이에 본 논문에서는 기존 강내방사선치료 시스템에 직장 피폭 선량을 줄여줄 수 있는 다양한 풍선형 카테터를 적용하였다. 카테터의 고정을 위해서는 풍선의 시작지점과 카테터 끝부분의 거리가 적절해야 하며 풍선의 크기 또한 오보이드 어플리케이터에 영향을 주지 않는 수준에서 큰 사이즈를 만족하는 수준으로 카테터를 선정하였다. 또한 선정된 카테터의 CT 영상을 토대로 풍선형 카테터 유무에 따른 탄뎀에서 직장까지 거리를 확인하고 직장에 피폭되는 선량의 감소를 확인하고자 하였다. 실험 결과 풍선의 시작지점과 카테터 끝부분의 거리, 오보이드 어플리케이터에 영향을 주지 않는 수준에서 최대한의 풍선 크기를 고려하여 7번 카테터를 선정하였다. 선정된 카테터의 CT 영상을 토대로 풍선형 카테터 유무에 따른 확장정도를 비교해본 결과 0.3 - 1 cm 의 거리 차이를 보임을 알 수 있었다. 또한 이러한 거리차이에 의해 약 32%의 감소를 보였다. 따라서 선택된 카테터의 실제 임상적용에 있어서도 기존의 직장견인기 및 젖은 거즈 등을 충분히 대체할 수 있을 것으로 사료된다. In order to reduce side effects such as rectal bleeding in the Brachytherapy, the rectal retractor and wet gauze have been used to increase the distance between the rectum and the tandem. However, there were disadvantages that it was difficult to insert through a narrow entrance into the vagina and poor reproducibility. Also, based on the CT image of the selected catheter, the distance from the tandem to the rectum with or without the balloon catheter was checked and the reduction of the dose to the rectum was confirmed. As a result of the experiment, catheter No. 7 was selected considering the maximum balloon size at a level that does not affect the distance between the start point of the balloon and the end of the catheter, and the ovoid applicator. Based on the CT image of the selected catheter, the degree of expansion according to the presence or absence of the balloon catheter was compared, and it was found that the distance difference was 0.3 - 1 cm. In addition, it was confirmed that a decrease of about 32% was observed due to this distance difference. Therefore, the actual clinical application of the selected catheter can be used as a substitute for the existing rectal retractor and wet gauze.

A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13-12.

Kang, Hyun-Cheol,Yu, Tosol,Lim, Do Hoon,Kim, Il Han,Chung, Woong-Ki,Suh, Chang-Ok,Choi, Byung Ock,Cho, Kwan Ho,Cho, Jae Ho,Kim, Jin Hee,Nam, Do-Hyun,Park, Chul-Kee,Hong, Yong-Kil,Kim, In Ah M. Nijhoff ; Kluwer Academic Publishers 2015 Journal of neuro-oncology Vol.125 No.1

<P>Although some existing evidence supports the addition of chemotherapy (CT) to radiation therapy (RT) for anaplastic oligodendroglioma treatment, controversy about both the criteria for suitable candidates and the optimal treatment schedule remains. We reviewed data from 376 newly diagnosed anaplastic oliogodendroglial tumor patients from nine Korean institutes were reviewed from 2000 to 2010. Total tumor removal was performed in 146 patients. More than 85??% of the entire patients received postoperative RT, and 59??% received CT. Approximately 50??% (n??=??189) received CT in addition to RT and 9??% (n??=??32) received CT only. A multivariate analysis revealed that younger age, frontal lobe location of the tumor, gross total removal, 1p/19q codeletion, and initial RT were associated with longer progression-free and overall survival rates. No difference was observed in outcomes from the treatment that included either temozolomide or PCV (procarbazine, lomustine, and vincristine) in addition to RT regardless of the 1p/19q deletion status. A clear improvement in progression-free and overall survival was observed for RT and combined CT/RT in compared with CT only. Postoperative RT appears to improve survival for entire group thus total removal and 1p/19q codeletion may not be sufficient criteria to omit RT as a treatment option. These results suggest that RT should continue to be offered as the standard treatment option for patients with anaplastic oligodendroglial tumors.</P>

Fluorodeoxyglucose positron-emission tomography ratio in non-small cell lung cancer patients treated with definitive radiotherapy

Kang, Hyun-Cheol,Wu, Hong-Gyun,Yu, Tosol,Kim, Hak Jae,Paeng, Jin Chul The Korean Society for Radiation Oncology 2013 Radiation Oncology Journal Vol.31 No.3

Purpose: To determine whether the maximum standardized uptake value (SUV) of [$^{18}F$] fluorodeoxyglucose uptake by positron emission tomography (FDG PET) ratio of lymph node to primary tumor (mSUVR) could be a prognostic factor for node positive non-small cell lung cancer (NSCLC) patients treated with definitive radiotherapy (RT). Materials and Methods: A total of 68 NSCLC T1-4, N1-3, M0 patients underwent FDG PET before RT. Optimal cutoff values of mSUVR were chosen based on overall survival (OS). Independent prognosticators were identified by Cox regression analysis. Results: The most significant cutoff value for mSUVR was 0.9 with respect to OS. Two-year OS was 17% for patients with mSUVR > 0.9 and 49% for those with mSUVR ${\leq}0.9$ (p = 0.01). In a multivariate analysis, including age, performance status, stage, use of chemotherapy, and mSUVR, only performance status (p = 0.05) and mSUVR > 0.9 (p = 0.05) were significant predictors of OS. Two-year OS for patients with both good performance (Eastern Cooperative Oncology Group [ECOG] ${\leq}1$) and mSUVR ${\leq}0.9$ was significantly better than that for patients with either poor performance (ECOG > 1) or mSUVR > 0.9, 23% (71% vs. 23%, p = 0.04). Conclusion: Our results suggested that the mSUVR was a strong prognostic factor among patients with lymph node positive NSCLC following RT. Addition of mSUVR to performance status identifies a subgroup at highest risk for death after RT.

Fluorodeoxyglucose positron-emission tomography ratio in non-small cell lung cancer patients treated with definitive radiotherapy

Hyun-Cheol Kang,Hong-Gyun Wu,Tosol Yu,Hak Jae Kim,Jin Chul Paeng 대한방사선종양학회 2013 Radiation Oncology Journal Vol.31 No.3

Purpose: To determine whether the maximum standardized uptake value (SUV) of [¹⁸F] fluorodeoxyglucose uptake by positron emission tomography (FDG PET) ratio of lymph node to primary tumor (mSUVR) could be a prognostic factor for node positive non-small cell lung cancer (NSCLC) patients treated with definitive radiotherapy (RT). Materials and Methods: A total of 68 NSCLC T1-4, N1-3, M0 patients underwent FDG PET before RT. Optimal cutoff values of mSUVR were chosen based on overall survival (OS). Independent prognosticators were identified by Cox regression analysis. Results: The most significant cutoff value for mSUVR was 0.9 with respect to OS. Two-year OS was 17% for patients with mSUVR > 0.9 and 49% for those with mSUVR ≤ 0.9 (p = 0.01). In a multivariate analysis, including age, performance status, stage, use of chemotherapy, and mSUVR, only performance status (p = 0.05) and mSUVR > 0.9 (p = 0.05) were significant predictors of OS. Two-year OS for patients with both good performance (Eastern Cooperative Oncology Group [ECOG] ≤ 1) and mSUVR ≤ 0.9 was significantly better than that for patients with either poor performance (ECOG > 1) or mSUVR > 0.9, 23% (71% vs. 23%, p = 0.04). Conclusion: Our results suggested that the mSUVR was a strong prognostic factor among patients with lymph node positive NSCLC following RT. Addition of mSUVR to performance status identifies a subgroup at highest risk for death after RT.

Analysis of maximum tolerated dose of mouse cardiac tissue response by irradiation method : FLASH vs. conventional radiation

Min-Young Choi,Hyun Kim,Sang Koo Kang,Sang Jin Lee,Kyoung Won Jang,Heuijin Lim,Manwoo Lee,Dong Hyeok Jeong,Young Min Moon,Jin Young Kim,Tosol Yu,Chul Won Choi,Wan Jeon 대한방사선방어학회 2023 대한방사선방어학회 학술발표회 논문요약집 Vol.2023 No.04